Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 267Thoracic 255Genitourinary 191Gastrointestinal 156Head & Neck 121Gynecologic 47Sarcoma 25Tumor-Agnostic 12Other solid neoplasm 10Dermatologic 5Endocrine 3CNS 3Other hematologic neoplasm 1Other 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1

Interventions

Rituximab 689Cyclophosphamide 614Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 228Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 175Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106Tacrolimus 105obinutuzumab 104Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Docetaxel × Lymphoid × Clear all
NCT00021242 2014-08-08

Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia

Children's Oncology Group

Phase 2 Completed
12 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡